ID   JeKo-1
AC   CVCL_1865
SY   Jeko-1; JEKO-1; JeKo 1; Jeko1; JEKO1; JEKO
DR   BTO; BTO:0006444
DR   EFO; EFO_0005387
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   ATCC; CRL-3006
DR   BioGRID_ORCS_Cell_line; 1542
DR   BioSample; SAMN01821569
DR   BioSample; SAMN01821639
DR   BioSample; SAMN03473289
DR   BioSample; SAMN10988454
DR   cancercelllines; CVCL_1865
DR   CCRID; 3101HUMTCHu194
DR   Cell_Model_Passport; SIDM01038
DR   ChEMBL-Cells; CHEMBL4295383
DR   ChEMBL-Targets; CHEMBL4296445
DR   CLS; 305078
DR   Cosmic; 1047110
DR   Cosmic; 1881781
DR   Cosmic; 2088016
DR   Cosmic; 2296999
DR   Cosmic; 2756237
DR   Cosmic-CLP; 1327765
DR   DepMap; ACH-000357
DR   DSMZ; ACC-553
DR   DSMZCellDive; ACC-553
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 1327765
DR   GEO; GSM95563
DR   GEO; GSM104460
DR   GEO; GSM119537
DR   GEO; GSM155081
DR   GEO; GSM155082
DR   GEO; GSM155083
DR   GEO; GSM629490
DR   GEO; GSM629491
DR   GEO; GSM887168
DR   GEO; GSM888240
DR   GEO; GSM907519
DR   GEO; GSM1044966
DR   GEO; GSM1044967
DR   GEO; GSM1044968
DR   GEO; GSM1044969
DR   GEO; GSM1374577
DR   GEO; GSM1669949
DR   GEO; GSM2322619
DR   GEO; GSM3150246
DR   IARC_TP53; 25017
DR   LiGeA; CCLE_844
DR   Lonza; 1060
DR   PharmacoDB; JeKo1_678_2019
DR   PRIDE; PXD004746
DR   PRIDE; PXD012087
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1865
DR   PubChem_Cell_line; CVCL_1865
DR   Wikidata; Q54898569
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=9753063;
RX   PubMed=12683869;
RX   PubMed=16448697;
RX   PubMed=16960149;
RX   PubMed=17332242;
RX   PubMed=21746927;
RX   PubMed=22460905;
RX   PubMed=25315077;
RX   PubMed=25355872;
RX   PubMed=25485619;
RX   PubMed=25688540;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26194763;
RX   PubMed=26439697;
RX   PubMed=27397505;
RX   PubMed=27697772;
RX   PubMed=28196595;
RX   PubMed=29666304;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Korean.
CC   Doubling time: 33 hours (PubMed=9753063); 26 hours (PubMed=25315077); 26.1 +- 1.1 hours (PubMed=26439697); ~50 hours (DSMZ=ACC-553).
CC   HLA typing: A*02:06,11:01; B*51:01,51:01; C*14:02,14:02; DQA1*03:02,03:02; DQB1*04:01,04:01; DRB1*04:05,14:103 (PubMed=25960936).
CC   HLA typing: A*02; B*51; C*14 (PubMed=25688540).
CC   HLA typing: A*02:06:01,02:06:01; B*51:01:01,51:01:01; C*14:02:01,14:02:01; DPA1*02:02:02,02:02:02; DPB1*05:01:01,05:01:01; DQA1*03:03:01,03:03:01; DQB1*04:01:01,04:01:01; DRA*01:01:01,01:01:01; DRB1*04:05:01,04:05:01 (DSMZCellDive=ACC-553).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=16448697).
CC   Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=16448697).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro58Glnfs*65 (c.173delC); ClinVar=VCV001394451; Zygosity=Heterozygous (PubMed=16448697).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Virome analysis using RNAseq.
CC   Genome ancestry: African=2.41%; Native American=0%; East Asian, North=63.65%; East Asian, South=31.67%; South Asian=0%; European, North=0%; European, South=2.27% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): ATCC; CCRID; Cosmic-CLP; DSMZ; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 9,12
ST   D13S317: 8,9
ST   D16S539: 12
ST   D18S51: 13,15
ST   D19S433: 13
ST   D21S11: 30,33.2
ST   D2S1338: 17,25
ST   D3S1358: 15,16
ST   D5S818: 10,13
ST   D7S820: 10,11
ST   D8S1179: 11,14
ST   FGA: 21,24
ST   Penta D: 12
ST   Penta E: 17,21
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 14
DI   NCIt; C4337; Mantle cell lymphoma
DI   ORDO; Orphanet_52416; Mantle cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   78Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 38
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=9753063; DOI=10.1046/j.1365-2141.1998.00911.x;
RA   Jeon H.J., Kim C.W., Yoshino T., Akagi T.;
RT   "Establishment and characterization of a mantle cell lymphoma cell
RT   line.";
RL   Br. J. Haematol. 102:1323-1326(1998).
//
RX   PubMed=12683869; DOI=10.5858/2003-127-0424-COMCLC;
RA   Amin H.M., McDonnell T.J., Medeiros L.J., Rassidakis G.Z.,
RA   Leventaki V., O'Connor S.L., Keating M.J., Lai R.;
RT   "Characterization of 4 mantle cell lymphoma cell lines. Establishment
RT   of an in vitro study model.";
RL   Arch. Pathol. Lab. Med. 127:424-431(2003).
//
RX   PubMed=16448697; DOI=10.1016/j.leukres.2005.11.013;
RA   Camps J., Salaverria I., Garcia M.J., Prat E., Bea S., Pole J.C.M.,
RA   Hernandez L., Del Rey J., Cigudosa J.C., Bernues M., Caldas C.,
RA   Colomer D., Miro R., Campo E.;
RT   "Genomic imbalances and patterns of karyotypic variability in mantle-cell
RT   lymphoma cell lines.";
RL   Leuk. Res. 30:923-934(2006).
//
RX   PubMed=16960149; DOI=10.1182/blood-2006-06-026500;
RA   Mestre-Escorihuela C., Rubio-Moscardo F., Richter J.A., Siebert R.,
RA   Climent J., Fresquet V., Beltran E., Agirre X., Marugan I., Marin M.,
RA   Rosenwald A., Sugimoto K.-j., Wheat L.M., Karran E.L., Garcia J.F.,
RA   Sanchez-Verde L., Prosper F., Staudt L.M., Pinkel D., Dyer M.J.S.,
RA   Martinez-Climent J.A.;
RT   "Homozygous deletions localize novel tumor suppressor genes in B-cell
RT   lymphomas.";
RL   Blood 109:271-280(2007).
//
RX   PubMed=17332242; DOI=10.1182/blood-2006-11-057208;
RA   Pinyol M., Bea S., Pla L., Ribrag V., Bosq J., Rosenwald A., Campo E.,
RA   Jares P.;
RT   "Inactivation of RB1 in mantle-cell lymphoma detected by
RT   nonsense-mediated mRNA decay pathway inhibition and microarray
RT   analysis.";
RL   Blood 109:5422-5429(2007).
//
RX   PubMed=21746927; DOI=10.1073/pnas.1018941108;
RA   Beltran E., Fresquet V., Martinez-Useros J., Richter-Larrea J.A.,
RA   Sagardoy A., Sesma I., Almada L.L., Montes-Moreno S., Siebert R.,
RA   Gesk S., Calasanz M.J., Malumbres R., Rieger M., Prosper F.,
RA   Lossos I.S., Piris M.A., Fernandez-Zapico M.E.,
RA   Martinez-Climent J.A.;
RT   "A cyclin-D1 interaction with BAX underlies its oncogenic role and
RT   potential as a therapeutic target in mantle cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:12461-12466(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=25315077; DOI=10.3109/10428194.2014.970548;
RA   Fogli L.K., Williams M.E., Connors J.M., Reid Y.A., Brown K.,
RA   O'Connor O.A.;
RT   "Development and characterization of a Mantle Cell Lymphoma Cell Bank
RT   in the American Type Culture Collection.";
RL   Leuk. Lymphoma 56:2114-2122(2015).
//
RX   PubMed=25355872; DOI=10.1128/JVI.02570-14;
RA   Cao S.-B., Strong M.J., Wang X., Moss W.N., Concha M., Lin Z.,
RA   O'Grady T., Baddoo M., Fewell C., Renne R., Flemington E.K.;
RT   "High-throughput RNA sequencing-based virome analysis of 50 lymphoma
RT   cell lines from the Cancer Cell Line Encyclopedia project.";
RL   J. Virol. 89:713-729(2015).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25688540; DOI=10.1002/cyto.a.22643;
RA   Maiga S., Brosseau C., Descamps G., Dousset C., Gomez-Bougie P.,
RA   Chiron D., Menoret E., Kervoelen C., Vie H., Cesbron A.,
RA   Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.;
RT   "A simple flow cytometry-based barcode for routine authentication of
RT   multiple myeloma and mantle cell lymphoma cell lines.";
RL   Cytometry A 87:285-288(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26194763; DOI=10.1182/blood-2015-01-624585;
RA   Bhatt S., Matthews J., Parvin S., Sarosiek K.A., Zhao D.-K., Jiang X.-Y.,
RA   Isik E., Letai A.G., Lossos I.S.;
RT   "Direct and immune-mediated cytotoxicity of interleukin-21 contributes
RT   to antitumor effects in mantle cell lymphoma.";
RL   Blood 126:1555-1564(2015).
//
RX   PubMed=26439697; DOI=10.18632/oncotarget.5954;
RA   Restelli V., Chila R., Lupi M., Rinaldi A., Kwee I., Bertoni F.,
RA   Damia G., Carrassa L.;
RT   "Characterization of a mantle cell lymphoma cell line resistant to the
RT   Chk1 inhibitor PF-00477736.";
RL   Oncotarget 6:37229-37240(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27697772; DOI=10.1182/blood-2016-06-720490;
RA   Chiron D., Bellanger C., Papin A., Tessoulin B., Dousset C., Maiga S.,
RA   Moreau A., Esbelin J., Trichet V., Chen-Kiang S., Moreau P.,
RA   Touzeau C., Le Gouill S., Amiot M., Pellat-Deceunynck C.;
RT   "Rational targeted therapies to overcome microenvironment-dependent
RT   expansion of mantle cell lymphoma.";
RL   Blood 128:2808-2818(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004;
RA   Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H.,
RA   Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H.,
RA   Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.;
RT   "Strategic therapeutic targeting to overcome venetoclax resistance in
RT   aggressive B-cell lymphomas.";
RL   Clin. Cancer Res. 24:3967-3980(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//